Xcellerex, Inc. and Humacyte, Inc. have entered into a strategic collaboration under which Xcellerex will develop a manufacturing process enabling the production of Humacyte’s lead regenerative drug product using its XDR single-use bioreactor system.

Humacyte’s product is a large vascular graft using the company’s platform technology for engineering human, extracellular matrix-based tissues that have properties similar to native tissues. The grafts will first be used for arterio-venous access in patients on hemodialysis and eventually would be used as a replacement of diseased or damaged blood vessels.

Xcellerex will provide development and product manufacturing in exchange for manufacturing development fees from Humacyte. Humacyte will use the initial grafts produced for preclinical development, and the parties may continue their collaboration for the large-scale manufacturing of vascular grafts for clinical and commercial use. Xcellerex’s FlexFactory will enable Humacyte to later scale up its production to meet late-stage clinical and commercial market demands.

“We are pleased to utilize our unique manufacturing technology and development know-how to enable the rapid development of a potent single-use manufacturing platform for Humacyte. Our technology offers Humacyte a cost-effective and novel manufacturing solution. We are excited to see our single use manufacturing technologies applied in such an important application that holds such great promise for significant advances in improving treatment options for patients,” stated Joseph Zakrzewski, Xcellerex’s chairman, president and chief executive officer.

Click here to learn more about Xcellerex